Department of Medical Oncology, Royal Marsden NHS Trust, London, UK.
Melanoma Res. 2013 Feb;23(1):79-81. doi: 10.1097/CMR.0b013e32835b554f.
Uveal melanoma (UM) is a rare disease with a distinct molecular profile. About half of the patients with UM eventually develop metastatic disease. The prognosis of these patients remains poor. Treatment options are limited and none of them have been able to show a survival benefit. Ipilimumab was the first agent to show a survival benefit in patients with cutaneous melanoma in a randomized trial; however, there is limited published evidence for its role in the management of advanced UM. Here, we report our experience of ipilimumab in five patients with advanced UM treated at an academic cancer centre in the UK. Two patients had durable stable disease and three developed progressive disease. Of the patients with stable disease, one maintained disease control at 11 months from the commencement of treatment with ∼10% reduction in tumour volume compared with the baseline, and the second patient progressed after 15 months. We also examined the tumour kinetics and response patterns that resembled that of ipilimumab in cutaneous melanoma. Given the lack of randomized trial data, our findings indicate that ipilimumab might be a reasonable treatment option for patients with advanced UM.
葡萄膜黑色素瘤（UM）是一种罕见疾病，具有独特的分子特征。约一半的 UM 患者最终会发展为转移性疾病。这些患者的预后仍然较差。治疗选择有限，没有一种治疗方法能够显示出生存获益。依匹单抗是在随机试验中显示出对皮肤黑色素瘤患者生存获益的第一种药物；然而，在晚期 UM 的治疗中，其作用的相关文献证据有限。在这里，我们报告了在英国一家学术癌症中心治疗的 5 名晚期 UM 患者使用依匹单抗的经验。两名患者有持久的稳定疾病，三名患者出现进展性疾病。在稳定疾病的患者中，一名患者在治疗开始后 11 个月与基线相比肿瘤体积减少约 10%，保持疾病控制，另一名患者在 15 个月后进展。我们还检查了肿瘤动力学和反应模式，这些模式类似于皮肤黑色素瘤中的依匹单抗。鉴于缺乏随机试验数据，我们的发现表明，依匹单抗可能是晚期 UM 患者的一种合理治疗选择。
